Melanoma and Immunotherapy

被引：41

作者：

Eggermont, Alexander M. M. ^{[1
]}

Schadendorf, Dirk ^{[2
]}

机构：

[1] Erasmus Univ, Dept Surg Oncol, MC Daniel den Hoed Canc Ctr, NL-3075 EA Rotterdam, Netherlands

[2] Univ Hosp Essen, Dept Dermatol, D-45122 Essen, Germany

来源：

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA | 2009年 / 23卷 / 03期

关键词：

Melanoma; Immunotherapy; Cytokines; Antibodies; Vaccines; Review; RANDOMIZED PHASE-III; METASTATIC MALIGNANT-MELANOMA; COOPERATIVE-ONCOLOGY-GROUP; TUMOR-INFILTRATING LYMPHOCYTES; HIGH-DOSE INTERLEUKIN-2; HIGH-RISK MELANOMA; STAGE-IV MELANOMA; CD8(+) T-CELLS; AMERICAN JOINT COMMITTEE; NODE-NEGATIVE MELANOMA;

D O I：

10.1016/j.hoc.2009.03.009

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

About 20% of all primary melanomas will spread. The likelihood of metastatic behavior correlates with prognostic factors such as tumor thickness, mitotic index, presence of ulceration, lymphocyte infiltration, age, gender, and anatomic site. Immunotherapies are developed for melanoma patients in stage IV who have distant metastases and in stage II to III patients in the adjuvant micrometastatic setting, where only a fraction of patients have widespread (microscopic) disease.

引用

页码：547 / +

页数：20

共 118 条

[71] IMPROVED SURVIVAL IN STAGE-III MELANOMA PATIENTS WITH GM2 ANTIBODIES - A RANDOMIZED TRIAL OF ADJUVANT VACCINATION WITH GM2 GANGLIOSIDE [J].

LIVINGSTON, PO ;

WONG, GYC ;

ADLURI, S ;

TAO, Y ;

PADAVAN, M ;

PARENTE, R ;

HANLON, C ;

CALVES, MJ ;

HELLING, F ;

RITTER, G ;

OETTGEN, HF ;

LLOYD, JO .

JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (05) :1036-1044

[72]

LOUAHED J, 2008, J CLIN ONCOL, V26

[73] Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma [J].

Mackensen, Andreas ;

Meidenbauer, Norbert ;

Vogl, Sandra ;

Laumer, Monika ;

Berger, Jana ;

Andreesen, Reinhard .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (31) :5060-5069

[74] Intratumoral injection of IL-12 plasmid DNA - results of a phase I/IB clinical trial [J].

Mahvi, D. M. ;

Henry, M. B. ;

Albertini, M. R. ;

Weber, S. ;

Meredith, K. ;

Schalch, H. ;

Rakhmilevich, A. ;

Hank, J. ;

Sondel, P. .

CANCER GENE THERAPY, 2007, 14 (08) :717-723

[75] Immunostimulatory monoclonal antibodies for cancer therapy [J].

Melero, Ignacio ;

Hervas-Stubbs, Sandra ;

Glennie, Martin ;

Pardoll, Drew M. ;

Chen, Lieping .

NATURE REVIEWS CANCER, 2007, 7 (02) :95-106

[76] Immunotherapy of established (pre) malignant disease by synthetic long peptide vaccines [J].

Melief, Cornelis J. M. ;

van der Burg, Sjoerd H. .

NATURE REVIEWS CANCER, 2008, 8 (05) :351-360

[77]

Middleton MR, 2000, BRIT J CANCER, V82, P1158

[78] Cancer regression in patients after transfer of genetically engineered lymphocytes [J].

Morgan, Richard A. ;

Dudley, Mark E. ;

Wunderlich, John R. ;

Hughes, Marybeth S. ;

Yang, James C. ;

Sherry, Richard M. ;

Royal, Richard E. ;

Topalian, Suzanne L. ;

Kammula, Udai S. ;

Restifo, Nicholas P. ;

Zheng, Zhili ;

Nahvi, Azam ;

de Vries, Christiaan R. ;

Rogers-Freezer, Linda J. ;

Mavroukakis, Sharon A. ;

Rosenberg, Steven A. .

SCIENCE, 2006, 314 (5796) :126-129

[79]

Morton DL, 2007, J CLIN ONCOL, V25

[80] ADOPTIVE IMMUNOTHERAPY OF ESTABLISHED PULMONARY METASTASES WITH LAK CELLS AND RECOMBINANT INTERLEUKIN-2 [J].

MULE, JJ ;

SHU, SY ;

SCHWARZ, SL ;

ROSENBERG, SA .

SCIENCE, 1984, 225 (4669) :1487-1489

← 3 4 5 6 7 8 9 10 11 12 →